• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Assessing New Drugs in Advanced Cancer: Beyond Randomised Evidence.

作者信息

Dodwell D, Shakir R

机构信息

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

出版信息

Clin Oncol (R Coll Radiol). 2021 Apr;33(4):e201-e202. doi: 10.1016/j.clon.2020.11.003. Epub 2020 Nov 20.

DOI:10.1016/j.clon.2020.11.003
PMID:33223383
Abstract
摘要

相似文献

1
Assessing New Drugs in Advanced Cancer: Beyond Randomised Evidence.评估晚期癌症中的新药：超越随机证据
Clin Oncol (R Coll Radiol). 2021 Apr;33(4):e201-e202. doi: 10.1016/j.clon.2020.11.003. Epub 2020 Nov 20.
2
Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.2014-2016 年支持欧洲药品管理局批准癌症药物的随机对照试验的设计特征、偏倚风险和报告：横断面分析。
BMJ. 2019 Sep 18;366:l5221. doi: 10.1136/bmj.l5221.
3
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.超根治性（广泛）手术与标准手术治疗晚期上皮性卵巢癌的初步细胞减灭术。
Cochrane Database Syst Rev. 2022 Aug 30;8(8):CD007697. doi: 10.1002/14651858.CD007697.pub3.
4
Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL).槲寄生提取物作为晚期胰腺癌标准治疗的辅助治疗的疗效：一项多中心、平行分组、双盲、随机、安慰剂对照临床试验（MISTRAL）的研究方案。
Trials. 2020 Sep 11;21(1):783. doi: 10.1186/s13063-020-04581-y.
5
Palliative interventions for controlling vaginal bleeding in advanced cervical cancer.晚期宫颈癌控制阴道出血的姑息性干预措施。
Cochrane Database Syst Rev. 2019 Mar 19;3(3):CD011000. doi: 10.1002/14651858.CD011000.pub3.
6
A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT).一项可行性研究，旨在为一项随机对照试验的设计提供信息，以确定低分子量肝素抗凝治疗癌症相关血栓形成（ALICAT）的最具临床疗效和成本效益的疗程。
Health Technol Assess. 2015 Oct;19(83):vii-xxiii, 1-93. doi: 10.3310/hta19830.
7
Antithrombotic drugs for carotid artery dissection.用于颈动脉夹层的抗血栓药物。
Cochrane Database Syst Rev. 2000(4):CD000255. doi: 10.1002/14651858.CD000255.
8
Palliative interventions for controlling vaginal bleeding in advanced cervical cancer.晚期宫颈癌控制阴道出血的姑息性干预措施。
Cochrane Database Syst Rev. 2015 May 1;2015(5):CD011000. doi: 10.1002/14651858.CD011000.pub2.
9
Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.用于治疗慢性丙型肝炎的金刚烷胺类药物与其他抗病毒药物的比较
Cochrane Database Syst Rev. 2014 Jun 17;2014(6):CD011132. doi: 10.1002/14651858.CD011132.pub2.
10
Clinical trials and the COVID-19 pandemic.临床试验与新冠疫情
Hell J Nucl Med. 2020 Jan-Apr;23(1):4-5. doi: 10.1967/s002449912014.

引用本文的文献

1
Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS.哌柏西利联合内分泌治疗的 HR+/HER2- 晚期乳腺癌患者的真实世界生活质量：来自 POLARIS 的 EORTC QLQ-C30 结果
Breast Cancer Res Treat. 2025 Feb;209(3):613-627. doi: 10.1007/s10549-024-07524-2. Epub 2024 Nov 25.
2
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial.哌柏西利联合内分泌治疗在激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌中的真实世界疗效：POLARIS试验的最终结果
Oncologist. 2024 Oct 30. doi: 10.1093/oncolo/oyae291.
3
Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.
帕博西尼联合芳香化酶抑制剂作为一线治疗方案用于绝经前/围绝经期转移性乳腺癌患者的真实世界肿瘤缓解情况。
Target Oncol. 2023 Jul;18(4):543-558. doi: 10.1007/s11523-023-00979-1. Epub 2023 Jul 10.
4
P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2- Metastatic Breast Cancer-A Podcast.P-REALITY X：哌柏西利联合芳香化酶抑制剂治疗激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的真实世界分析——播客
Target Oncol. 2023 May;18(3):321-326. doi: 10.1007/s11523-023-00968-4. Epub 2023 May 6.
5
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.哌柏西利联合芳香化酶抑制剂治疗激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌的总生存的真实世界研究
NPJ Breast Cancer. 2022 Oct 11;8(1):114. doi: 10.1038/s41523-022-00479-x.